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Abstract
Background:  Genotypic assays based on DNA sequencing of part or the whole reverse
transcriptase (RT)- and protease (PR)-coding regions of the human immunodeficiency virus type 1
(HIV-1) genome have become part of the routine clinical management of HIV-infected individuals.
However, the results are difficult to interpret due to complex interactions between mutations
found in viral genes.
Results: DR_SEQAN is a tool to analyze RT and PR sequences. The program output includes a
list containing all of the amino acid changes found in the query sequence in comparison with the
sequence of a wild-type HIV-1 strain. Translation of codons containing nucleotide mixtures can
result in potential ambiguities or heterogeneities in the amino acid sequence. The program
identifies all possible combinations of 2 or 3 amino acids that derive from translation of triplets
containing nucleotide mixtures. In addition, when ambiguities affect codons relevant for drug
resistance, DR_SEQAN allows the user to select the appropriate mutation to be considered by the
program's drug resistance interpretation algorithm. Resistance is predicted using a rule-based
algorithm, whose efficiency and accuracy has been tested with a large set of drug susceptibility data.
Drug resistance predictions given by DR_SEQAN were consistent with phenotypic data and
coherent with predictions provided by other publicly available algorithms. In addition, the program
output provides two tables showing published drug susceptibility data and references for mutations
and combinations of mutations found in the analyzed sequence. These data are retrieved from an
integrated relational database, implemented in Microsoft Access, which includes two sets of non-
redundant core tables (one for combinations of mutations in the PR and the other for combinations
in the RT).
Conclusion: DR_SEQAN is an easy to use off-line application that provides expert advice on HIV
genotypic resistance interpretation. It is coded in Visual Basic for use in PC/Windows-based
platforms. The program is freely available under the General Public License. The program (including
the integrated database), documentation and a sample sequence can be downloaded from http://
www2.cbm.uam.es:8080/lmenendez/DR_SEQAN.zip
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Background
According to recent reports of the World Health Organiza-
tion, there are more than 40 million people infected with
the human immunodeficiency virus (HIV) around the
world [1]. Sixty-five percent of them live in sub-Saharan
Africa. In Western Europe, an estimated 720,000 people
are living with HIV, and in the United States this figure
goes up to 1,200,000. Since the introduction in the mid-
90s of highly active antiretroviral therapies, mortality due
to HIV infection has decreased in those countries where
the population has access to antiretroviral treatments.
However, even in developed countries the number of
infected people is increasing.
At present, there are around 20 compounds approved for
clinical use against HIV. These drugs are usually either
inhibitors of the viral reverse transcriptase (RT), or inhib-
itors of the viral protease (PR), although a novel peptide
(known as enfuvirtide) which blocks viral entry by inter-
fering with the process involving fusion of the viral enve-
lope and the host cell membrane has been recently
licensed [2]. Despite the introduction of potent antiretro-
viral therapies, drug resistance is still a major hurdle to
achieve complete suppression of viral replication in many
patients, and compromises the long-term efficacy of
antiretroviral regimens.
Since the introduction of antiretroviral therapy with RT
and/or PR inhibitors, evidence of drug resistance has been
observed and mutations conferring drug resistance have
been identified [3,4]. Since the number of approved
antiretroviral drugs has been steadily increasing, the need
for optimizing the treatment based on genotypic informa-
tion is becoming more evident. Antiretroviral drug resist-
ance testing has become part of the routine clinical
management of HIV-infected individuals in developed
countries. Genotypic assays based on DNA sequencing of
the HIV-1 pol gene (including part of the RT-coding region
and the whole PR) are frequently done to help physicians
choose antiretroviral drugs by identifying drug resistance
mutations in the plasma virus of infected patients. These
assays have a faster turnaround time, are easier to perform
and are less expensive than phenotypic assays (for
reviews, see [5,6]). Nevertheless, a major difficulty with
resistance genotyping is the interpretation of results.
A large number of genotypic resistance interpretation
tools have been developed in recent years and are availa-
ble by different means [7,8]. These include lists of muta-
tions relevant for drug resistance, rule-based algorithms,
and mathematical models based on correlations found in
databases containing genotypes and drug susceptibility
data [4,9-15]. Although approaches based on mathemati-
cal models such as the support vector machine algorithm
[11] or the linear regression model [10] provide objective
quantitative assessments of drug resistance, rule-based
algorithms are more efficient when estimating the effects
of mutations underrepresented in the genotype-pheno-
type data sets used by those programs. In addition, some-
times there is a lack of consistency between clinical
response and phenotypic data that can be corrected only
by specific rules. Despite the large number of studies
focusing on the role of mutations in drug resistance, there
are many questions unanswered on the contribution of
amino acid substitutions in the viral resistance phenotype
and its clinical implications.
In this scenario, DR_SEQAN (Drug Resistance SEQuence
ANalyzer) has been developed to identify those mutations
in the PR- and RT-coding regions of the HIV-1 genome
that lead to amino acid substitutions (i.e. non-synony-
mous mutations), which are subsequently classified as rel-
evant or non-relevant for drug resistance. An
interpretation algorithm is used to predict viral drug sus-
ceptibility. In addition, the program provides a report
with published phenotypic data for mutations or combi-
nations of mutations found in the query sequence.
Implementation
The source code of DR_SEQAN has been written in Visual
Basic 6.0 (Microsoft) (source code available on request),
and developed for a PC/Windows environment.
Sequence data
HIV drug resistance tests involve the determination of the
viral genotype. For this purpose, viral RNA is extracted
from plasma and the RT- and PR-coding regions are
amplified by using a nested reverse-transcription
polymerase chain reaction (RT-PCR). RT-PCR products
are then subjected to automatic sequencing. Data input
for DR_SEQAN is the obtained proviral DNA sequence.
Sequence data can be introduced either as a text file (with-
out headings or in FASTA format), or as a list of muta-
tions. The query sequence can be uploaded from a file (i.e.
FILE.TXT), or pasted in the appropriate window.
When the program is executed, the coding nucleotide
sequence is automatically translated. The obtained amino
acid sequences are then compared with the PR and RT
sequences of the reference wild-type strain HIV-1HXB2
[GenBank:K03455], using BLAST [16]. The obtained
alignment is used to identify amino acid differences
between the query and reference sequences. For the pro-
gram to run, the analyzed sequence must be at least 260
nucleotides long. Although DR_SEQAN accepts partial
nucleotide sequences, they should contain one of the con-
served motifs ('DTGAD' or 'GPTP') of the PR [17] to allow
PR sequence analysis.BMC Infectious Diseases 2006, 6:44 http://www.biomedcentral.com/1471-2334/6/44
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It should be noted that conventional population-based
sequence approaches allow the characterization of the
dominant viral species, but do not reliably detect variants
that comprise less than 20 % of the total virus population.
However, the presence of resistant minorities can lead to
sequence heterogeneities that often result in unidentifia-
ble residues. The program accepts mixtures of 2, 3 or 4
nucleotides in any position of the query sequence when
the appropriate single-letter codes are used: B for (for the
mixture of C, G and T), D (for A + G + T), H (for A + C +
T), K (for G + T), M (for A + C), N (for A + C + G + T), R
(for A + G), S (for C + G), V (for A + C + G), W (for A + T),
and Y (for C + T). DR_SEQAN keeps to a minimum the
number of unidentified residues (typically represented
with an 'X'), by assuming all cases where mixtures of 2, 3
or 4 nucleotides do not result in an ambiguous amino
acid sequence determination (i.e. the triplet GGN is trans-
lated as G). In addition, it provides information on any
potential combination of 2 or 3 amino acids that could be
derived from codons containing nucleotide mixtures (i.e.
TTM is translated as [F/L], BTC as [F/L/V], etc.).
Prediction algorithm
Sequence alignments allow the identification of amino
acid differences between the query sequence and the
sequence of the wild-type HIV-1 clone used as a reference.
Then, DR_SEQAN makes a drug resistance prediction
using a rule-based algorithm based on current evidence
and authors' expertise. The rules used for the genotypic
interpretation are based on correlations between the
effects of mutations and/or combinations of mutations in
drug resistance as observed in vitro or in the clinical setting
[15]. The rules used by DR_SEQAN version 1.0 are given
as supplementary information [see Additional file 1], but
are also accessible through the help command of the pro-
gram.
It should be noted that only certain residues could be rel-
evant for resistance when nucleotide mixtures appear in
the sequence. For example, at position 215 of the RT-cod-
ing region, the substitutions T215F and T215Y contribute
to zidovudine resistance, but T215D or T215S have no
impact on drug susceptibility [3,4]. In this case, the signif-
icance of T215X could be uncertain. However, when this
uncertainty occurs at codons related to drug resistance, the
program displays a window where the sequence ambigui-
ties (derived amino acid mixtures) are shown together
with the actual codon found in the sequence. A series of
buttons allow the user to select for the wild-type or the
appropriate mutation to be considered by the prediction
algorithms. If no selection is made, the prediction algo-
rithm assumes that the mutation found at the correspond-
ing position would be the one having the largest effect on
drug resistance.
Phenotypic data
The impact on phenotypic resistance of mutations found
in the query sequence is retrieved from an integrated rela-
tional database (implemented in Microsoft Access),
which includes 2 sets of non-redundant core tables (one
for the PR and the other one for the RT). These tables con-
tain information on phenotypic drug susceptibility (fold-
increase of the IC50 relative to the wild-type reference
virus) as well as references for each drug and combination
of amino acid substitutions. The database contains 6,835
entries, with drug susceptibility data for all 19 licensed
compounds, collected from 263 published papers [15].
Results and discussion
The interpretation of genotypic drug resistance tests is dif-
ficult due to the complex mutational patterns that appear
in HIV isolates from infected patients, particularly those
that have been heavily-treated. Mutational pattern com-
plexity increases as more new drugs become part of the
antiretroviral treatments. Available genotypic interpreta-
tion algorithms range from sophisticated machine learn-
ing-based methods to look-up tables [7,8]. However,
algorithms need to be updated frequently, and any addi-
tional information on the effects of specific mutations on
drug resistance should be helpful to make a decision on
treatment.
The output generated by DR_SEQAN (Figure 1) consists
of three parts: (i) a list of amino acid substitutions in the
PR- and RT-coding regions, indicating those changes
related to drug resistance; (ii) a prediction of the expected
level of resistance to all available antiretroviral drugs, as
determined using a rule-based algorithm; and (iii), a chart
with published drug susceptibility data for each mutation
or combination of mutations found in the query
sequence, where the relative increases of the IC50s for each
inhibitor are given.
The program makes a drug resistance prediction using a
rule-based algorithm [see Additional file 1]. Results, rep-
resenting high-level, significant or partial resistance to
each inhibitor are indicated in red, orange or yellow,
respectively (Figure 1). Green is used to indicate that the
virus is expected to remain susceptible to the drug. When
either the PR or the RT sequence is missing, resistance to
the corresponding inhibitors cannot be predicted, and the
lack of information is represented in white.
DR_SEQAN's interpretation algorithm is an updated ver-
sion of an earlier set of rules that showed good perform-
ance when tested on clinical samples [18]. Now, we have
compared the predictions given by DR_SEQAN with those
obtained using four HIV-1 genotypic resistance interpreta-
tion algorithms, available from Virology Networks (Retro-
gram version 1.6) [19], the French Agency for AIDSBMC Infectious Diseases 2006, 6:44 http://www.biomedcentral.com/1471-2334/6/44
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Research (ANRS algorithm, version 9/04) [20,21], the
Stanford University HIV Drug Resistance Database
(HIVDB version 3/05) [11,22], and the Rega Institute
(RegaInst version 6.2) [9]. These algorithms use a three- or
four-level category classification of predicted resistance,
with interpretations such as 'high-level resistance', 'inter-
mediate resistant', 'possible resistance', or 'recommended
drug to be used for treatment', among others. Equivalen-
cies between the recommendations given by the algo-
rithms are shown in Table 1.
There are some relevant differences between the algorithm
of DR_SEQAN and the others. First, DR_SEQAN provides
a drug resistance interpretation for each of the 19 RT and
PR inhibitors licensed for treatment of HIV infection,
while providing updated phenotypic data collected from
the literature. Second, there are differences in
DR_SEQAN's algorithm that affect amino acid substitu-
tions that are not considered by the others. For example,
Retrogram does not take into account several mutations
that could be relevant for drug resistance, such as R8Q,
K20T, L33F, E34Q, M36L, G48M, I54A, I54S, Q58E, A71I,
and G73A/C/S in the PR-coding region. Third,
DR_SEQAN warns on the presence and number of antag-
onistic mutations, assuming their consequences for zido-
vudine (AZT), tenofovir, delavirdine and amprenavir
resistance. The rules used by other algorithms (i.e. Retro-
gram, ANRS or RegaInst) do not take into account the
effects of antagonistic mutations, or make a limited used
of them (i.e. HIVDB assumes only the suppressive effects
DR_SEQAN output window Figure 1
DR_SEQAN output window. (A) List of mutations found in the PR- and RT-coding regions. (B) Predicted resistance as 
determined with the program's algorithm (red, high-level; orange, significant level; yellow, partial resistance; green, drug-sensi-
tive). (C) Drug susceptibility data reported in the literature for different combinations of mutations found in the query 
sequence. (D) References and IC50 values reported for the indicated inhibitor and combination of mutations (this window 
appears by double clicking on the corresponding cell).
A
B C
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of K65R, L74V, L100I, Y181C and M184I/V on AZT resist-
ance, and M184V on tenofovir resistance mediated by
K65R). However, DR_SEQAN assumes the effects of
mutations such as W88G, E89K or E89G that confer resist-
ance to foscarnet while increasing AZT susceptibility, or
K20T whose antagonist effect on amprenavir resistance
has been demonstrated [14,15]. Another relevant feature
of DR_SEQAN is that its output shows those positions
involved in drug resistance, whose sequence has not been
provided.
The prediction accuracy of the algorithms was tested using
the Genotype-Phenotype Dataset, version 2.0 (release on
Nov 1, 2004), available from the Stanford database [21].
This data set contains drug susceptibility data obtained
with the PhenoSense™ assay, available from Monogram
Biosciences Inc. (formerly Virologic) [22]. After excluding
the data of those RTs whose mutation lists were not com-
plete, and the data of PR sequences having poorly defined
amino acid substitutions (i.e. entries 54307 to 54356), we
obtained new data sets with phenotypic information for
191 combinations of amino acid changes in the RT and
571 in the PR. For each isolate, the available phenotypic
data include a list of values representing the fold-increase
of the IC50 for one or more antiretroviral drugs, obtained
in comparison with a wild-type HIV clone.
Since the significance of each category might be different
depending on the algorithm, we decided to compare the
predictions by testing their ability to discriminate between
susceptible and non-susceptible isolates. For most drugs,
predictions given by DR_SEQAN were roughly similar to
those obtained with other algorithms (Table 2).
DR_SEQAN showed higher accuracy in the prediction of
susceptibility to RT inhibitors, with figures above 75 % for
all RT inhibitors, except stavudine. In contrast, our pro-
gram was somewhat less efficient in the detection of iso-
lates sensitive to several PR inhibitors, due to the
conservative rules of the algorithm that often predicts par-
tial resistance with only two secondary mutations. How-
ever, the percentage of drug-resistant isolates predicted to
be susceptible to PR and nonnucleoside RT inhibitors was
very low (estimated within the 4.6 – 16.3 % range) (Table
3). These type of errors were also relatively uncommon for
nucleoside RT inhibitors (<20 %). The higher percentages
obtained with various nucleoside RT inhibitors are a con-
sequence of the lack of correlation between phenotypic
data and clinical response observed with analogues whose
resistance is mediated by the acquisition of significant
ATP-dependent excision activity ([25], and references
therein).
The comparative analysis shows that DR_SEQAN pro-
vides coherent results with the other algorithms, while
avoiding the large discrepancies between predictions and
phenotypic data found with various drugs using other
interpretation algorithms. Thus, discrepancies between
the phenotypic data collected in the Stanford data set and
the predictions given by DR_SEQAN occurred in only
16.3 % of the isolates predicted to be susceptible to lopi-
navir, while in the case of Retrogram, ANRS or RegaInst
algorithms this figure increased up to >37 %, using a cut-
off value of 1.7-fold (Table 3). Moreover, the higher accu-
racy of DR_SEQAN was also observed using a clinically
relevant cut-off value of 10-fold. Reduced accuracies in
lopinavir predictions could be attributed to inefficient
rules that were established when the available informa-
tion on lopinavir resistance was rather limited.
Other discrepancies between the predictions given by the
different algorithms have been observed with zalcitabine,
didanosine, stavudine and abacavir. For those RT inhibi-
tors, the interpretation algorithms of DR_SEQAN and
ANRS showed similar results, while displaying higher
accuracy in the detection of isolates susceptible to nucleo-
side RT inhibitors (Table 2). In comparison with the other
algorithms, thymidine analogue resistance mutations
have a smaller impact on predictions carried out with
DR_SEQAN or with the ANRS algorithm. However, muta-
tional patterns conferring resistance to zalcitabine, dida-
Table 1: Consensus categories and their significance according to the algorithms used in the comparison.
Algorithms
Category DR_SEQAN Retrogram ANRS HIVDB RegaInst
S (green) Virus expected to be
susceptible to the drug
The corresponding drug can
be used (susceptible)
Susceptible Potential low-level 
resistance 
(or susceptible)
Susceptible
I (yellow) Partial/low-level resistance Consider the use of this drug
if no 'S' class drugs are available
Possible resistance Intermediate/low-level 
resistance
Intermediate 
resistant
IR (orange) Significant resistance predicted Consider the use of this drug if no
'S' or 'I' class drugs are available
R (red) Predicted resistance levels
are very high
To be used only if 'S', 'I' or 'IR'
classes are not available
Resistance High-level resistance ResistantBMC Infectious Diseases 2006, 6:44 http://www.biomedcentral.com/1471-2334/6/44
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nosine, stavudine and abacavir are complex, and the
contribution of thymidine analogue resistance mutations
(M41L, D67N, K70R, L210W, T215F/Y, K219Q/E) is
poorly-defined in vivo, particularly when other mutations
such as L74V or M184V are present [4,15].
Although phenotypic data and predictions obtained with
different interpretation methods give consistent results, it
should be noted that phenotypic data do not always cor-
relate well with the clinical response in infected patients
[8,23,26], and a validation of currently used genotypic
Table 3: Analysis of discrepancies between phenotypic data and the predictions obtained with different interpretation algorithms.a
Interpretation algorithm
Inhibitor DR_SEQAN Retrogram ANRS HIVDB RegaInst
Zidovudine (AZT) 2.8 (36) 0 (31) 0 (35) 0 (33) 2.8 (36)
Zalcitabine (ddC) 11.1 (99) 0 (20) n.d.b n.d. 1.4 (27)
Didanosine (ddI) 17.8 (118) 0 (21) 11.7 (94) 0 (30) 3.3 (30)
Lamivudine (3TC) 3.9 (51) 2.1 (48) 7.1 (56) 4.2 (48) 4.2 (48)
Stavudine (d4T) 12.1 (58) 2.9 (34) 0 (35) 0 (32) 0 (57)
Abacavir (ABC) 19.8 (81) 0 (24) 19 (84) 3.3 (30) 3.8 (26)
Nevirapine (NVP) 13.4 (67) 14.0 (50) 8.8 (68) 4.8 (63) 4.0 (50)
Delavirdine (DLV) 5.4 (93) 3.3 (61) n.d. 3.4 (88) 3.2 (62)
Efavirenz (EFV) 11.5 (87) 12.8 (47) 10.8 (65) 1.6 (63) 6.3 (48)
Saquinavir (SQV) 8.9 (20 1 ) 8 . 1  ( 2 2 2 )3 0 . 0  ( 3 5 7 )6 . 4  ( 2 1 8 )1 4 . 4  ( 2 6 3 )
Ritonavir (RTV) 4.6 (175) 5.4 (188) 6.5 (213) 4.1 (219) 7.6 (198)
Indinavir (IDV) 5.8 (190) 5.4 (185) 6.2 (211) 4.9 (205) 7.9 (228)
Nelfinavir (NFV) 5.6 (160) 6.0 (16 8 )1 3 . 9  ( 2 0 9 )2 . 9  ( 1 7 0 )1 3 . 0  ( 2 0 0 )
Amprenavir (APV) 8.9 (223) 11.6 (216) 42.0 (483) 3.8 (208) 19.4 (304)
Lopinavir (LPV) 16.3 [0]c (43) 54.8 [28.6] (84) 61.6 [22.3] (112) 3.2 [3.2] (31) 37.5 [17.9] (56)
a The reported values are percentages of isolates that are predicted to be sensitive to the inhibitor (S category in Table 1), but show a fold-increase 
of the IC50 for the inhibitor, which is above the cut-off values given in Table 2. Numbers in parenthesis indicate the total number of isolates 
predicted to be susceptible to the drug in the analyzed data set.
b n.d., not determined.
c The numbers shown between brackets represent the percentages obtained using a 10-fold cut-off value.
Table 2: Prediction accuracy of DR_SEQAN in comparison with other publicly available algorithms.
Inhibitor Total no. of 
isolates
No. of drug-
susceptible isolatesa
Percentage of drug-susceptible isolates correctly predicted by the algorithms
DR_SEQAN Retrogram ANRS HIVDB RegaInst
Zidovudine (AZT) 135 48 79.2 64.6 72.9 68.8 72.9
Zalcitabine (ddC) 130 106 83.0 18.9 n.d.b n.d. 24.5
Didanosine (ddI) 136 104 93.3 20.2 79.8 28.8 27.9
Lamivudine (3TC) 138 59 83.1 79.7 88.1 78.0 78.0
Stavudine (d4T) 136 85 60.0 38.8 41.2 37.6 67.1
Abacavir (ABC) 134 75 88.0 32.0 89.3 38.7 33.3
Nevirapine (NVP) 183 66 87.9 65.2 93.9 90.9 72.7
Delavirdine (DLV) 183 103 83.5 57.3 n.d. 82.5 58.3
Efavirenz (EFV) 180 97 79.4 48.5 67.0 64.9 49.5
Saquinavir (SQV) 548 278 65.8 73.4 89.9 73.4 80.9
Ritonavir (RTV) 510 237 67.9 75.1 84.0 88.6 77.2
Indinavir (IDV) 529 250 70.8 70.0 79.2 78.0 84.0
Nelfinavir (NFV) 567 224 66.1 70.5 80.4 73.7 77.7
Amprenavir (APV) 527 282 72.0 67.7 99.3 70.9 86.9
Lopinavir (LPV) 203 42 (99) 85.7 (43.4) 88.1 (60.6) 100 (87.9) 69.0 (29.3) 81.0 (45.5)
a Drug susceptible isolates were defined as those that in comparison with the wild-type reference clone showed a fold-increase of the IC50 value for 
each drug, which was below 1.8-fold for AZT, 2.6-fold for ddC, 2-fold for ddI and d4T, 9-fold for 3TC, 4.5-fold for ABC, 6-fold for NVP, DLV and 
EFV, 1.7-fold for SQV and LPV, 2.5-fold for RTV and IDV, 3.6-fold for NFV and 2-fold for APV. Those cut-off values were consistent with those 
previously defined for the PhenoSense™ assay [24]. In the case of LPV, the values shown between parenthesis refer to the clinically relevant cut-off 
value of 10-fold [24].
b n.d., not determinedBMC Infectious Diseases 2006, 6:44 http://www.biomedcentral.com/1471-2334/6/44
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interpretation methods using clinical parameters (i.e. viral
load, CD4 counts, etc.) would be necessary to make a
more realistic assessment of the efficiency of DR_SEQAN
in comparison with the other algorithms.
Together with the resistance interpretation, DR_SEQAN
provides information on the effects of mutations on drug
susceptibility. Thus, for each antiretroviral drug and com-
bination of amino acid substitutions, the program dis-
plays the fold-increase of the IC50 relative to the wild-type
reference virus, as determined in phenotypic assays. This
value, which represents an average fold-increase of the
IC50 when two or more papers report on the same combi-
nation of mutations, is obtained from the associated data-
base. As in the prediction, drug resistance levels are
highlighted in red, orange, yellow or green (Figure 1).
High-level or significant resistance implies a >50-fold- or
a >15-fold-increase of the IC50 (indicated in red or orange,
respectively), relative to the value obtained with a refer-
ence HIV clone. For partial resistance (yellow), the
increase of the IC50  should be higher than a specific
threshold defined for each inhibitor: 6-fold for nevirap-
ine; 5-fold for delavirdine and efavirenz; 4-fold for zido-
vudine, zalcitabine, didanosine, lamivudine and
emtricitabine; 3-fold for abacavir and atazanavir; 2.5-fold
for stavudine, indinavir, nelfinavir, amprenavir and lopi-
navir; and 2-fold for tenofovir, saquinavir, ritonavir and
tipranavir. When the phenotypic data reveal that a combi-
nation of mutations does not confer resistance, the corre-
sponding values are shown in green. On the other hand, a
purple background is used to indicate that the mutation
leads to a virus with increased susceptibility to the drug.
Since IC50 values reported in the literature have been
obtained using different phenotypic assays, the cut-off
values used in the report have been arbitrarily chosen, and
are different from those used in Tables 2 and 3, which cor-
respond with specific cut-off values determined for the
PhenoSense™ assay [24]. In addition to the fold-increases
of the IC50, the user can obtain a list of bibliographic
entries with the reported IC50 values and their correspond-
ing links to PubMed by double-clicking on the corre-
sponding cell.
Conclusion
DR_SEQAN is an easy to use off-line application that pro-
vides expert advice on HIV genotypic resistance interpre-
tation. As input data, the program uses HIV PR- and/or
RT-coding sequences or a list of mutations. When the
DNA sequence is provided, DR_SEQAN aligns the query
sequence with a wild-type one, and identifies the muta-
tions that are relevant for drug resistance. These mutations
are used to run a genotypic interpretation algorithm that
provides an estimate of the expected levels of resistance to
all currently used antiretroviral drugs. The predictions
given by DR_SEQAN are consistent with those provided
by other algorithms and correlate well with phenotypic
data. In addition, the program shows published pheno-
typic data for all possible combinations of mutations
found in the query sequence. This information should be
helpful to make an assessment on the robustness of the
drug resistance prediction, based on available data col-
lected from the literature.
Availability and requirements
The entire DR_SEQAN software (including the drug sus-
ceptibility database) and documentation will be freely
available for the scientific community from http://
www2.cbm.uam.es:8080/lmenendez/DR_SEQAN.zip.
Periodic information on algorithm updates and/or new
releases of the drug susceptibility database will be given in
our lab's web page at http://www.cbm.csic.es or http://
www.cbm.uam.es (see research on Immunology and
Virology). Currently, DR_SEQAN is available for PCs run-
ning Windows operating systems.
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